Nuveen’s Climb Bio CLYM Stock Holding History

Nuveen’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-39,034	Closed	-$47.6K	–	3445
2025 Q1	$47.6K	Hold	39,034	–	–	﹤0.01%	3261
2024 Q4	$70.3K	Hold	39,034	–	–	﹤0.01%	3305
2024 Q3	$199K	Buy	+39,034	New	+$276K	﹤0.01%	3222

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Nuveen's CLYM Position: Q2 2025 in Review

Nuveen sold out of Climb Bio (CLYM) in Q2 2025, closing a stake of 39,034 shares — an estimated $47.6K sold.

Nuveen first reported a position in CLYM in Q3 2024 and held it in 3 quarters. The position peaked at $199K in Q3 2024. 69 funds tracked by Wall St. Rank hold CLYM as of Q2 2025.

Nuveen reported no remaining Climb Bio position as of Q2 2025 after selling out during the quarter.
Nuveen sold 39,034 Climb Bio shares in Q2 2025, an estimated $47.6K.
Nuveen first reported a position in Climb Bio in Q3 2024 and held it in 3 quarters.
Nuveen's Climb Bio position peaked at $199K in Q3 2024.
69 funds tracked by Wall St. Rank held Climb Bio as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.